Aclaris Therapeutics will hold a conference call to discuss top-line results for its Phase 2b clinical trial of zunsemetinib in subjects with rheumatoid arthritis, and issued a press release announcing the results.
AI Assistant
ACLARIS THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.